YDESW

YD Bio Limited Warrants

52W High Breakout

$0.35$0.03 (-7.89%)

Loading Chart...

Institutional Signal // Day Trade Edge:Neutral / No Active Setup Today

Scan Active Universe on Day Trade Edge

Key Statistics

Market Cap—

Forward P/E—

EPS (TTM)—

52-Week Return—

50-Day Moving Avg—

200-Day Moving Avg—

Volume Today107

Avg Volume107

Day Range$0.35 – $0.35

52-Week Range$0.35 – $0.35

Open Price$0.35

Previous Close$0.38

Company Profile

Description

YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.

CEO

Dr. Ethan Shen Ph.D.

Website

ydesgroup.com

SEC Filings

EDGAR Filings

Exchange Listing

Nasdaq.com

Company Profile

Description

CEO

Dr. Ethan Shen Ph.D.

Website

ydesgroup.com

SEC Filings

EDGAR Filings

Exchange Listing

Nasdaq.com

YDESW

Key Statistics

Company Profile

Company Profile

Recent News

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

Recent News

Company Profile

Recent News

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations